Filing Summary
Business Context and Reporting Period
Xeris Biopharma Holdings, Inc. filed a Form 8-K on September 27, 2023, reporting an agreement entered into on September 26, 2023, to exchange a portion of Xeris Pharmaceuticals, Inc.’s outstanding 5.00% Convertible Senior Notes due 2025 for new senior unsecured convertible notes due 2028.
Transaction and Key Financial Terms
- The Company agreed to exchange $31.975 million aggregate principal amount of Existing Notes for $33.574 million aggregate principal amount of New Notes.
- The New Notes will bear cash interest at 8.00% annually, payable semi-annually beginning January 15, 2024.
- The New Notes mature on July 15, 2028, unless earlier converted, redeemed, or repurchased.
- Following the transaction, approximately $15.2 million principal amount of Existing Notes is expected to remain outstanding under unchanged terms.
- The New Notes will be senior, unsecured obligations of the Company and guaranteed by Xeris Pharmaceuticals, Inc.
- The initial conversion rate is 326.7974 shares per $1,000 principal amount, equivalent to an initial conversion price of approximately $3.06 per share.
- At the maximum stated make-whole conversion rate, up to approximately 18.45 million shares could be issued, subject to adjustment.
Material Changes Versus the Prior Comparable Period
- The transaction replaces $31.975 million of 5.00% debt due 2025 with $33.574 million of 8.00% convertible debt due 2028.
- The exchange extends the maturity of the exchanged principal but increases the applicable stated interest rate from 5.00% to 8.00%.
- The transaction increases potential equity dilution through the conversion feature of the New Notes.
Outlook, Conditions, Risks, and Unusual Items
- Closing was expected on September 29, 2023, subject to customary closing conditions.
- The New Notes may be converted by holders before the second scheduled trading day preceding maturity, subject to the applicable conversion rate.
- Holders may require repurchase at par upon specified Fundamental Change events, subject to conditions.
- The Company may redeem the New Notes beginning July 20, 2026, only if specified stock-price and conversion-price thresholds are met.
- The transaction was privately negotiated and conducted under the Securities Act Section 4(a)(2) exemption. The New Notes and related conversion shares were not registered under the Securities Act.
- Specified reporting covenant defaults may result in special interest as the exclusive remedy for up to 360 days if the Company elects that remedy.
- Forward-looking transaction expectations depend partly on participating noteholders delivering their Existing Notes as required. The filing provides no revenue, profit, cash-flow, margin, cash-balance, or liquidity guidance.
Investor Verification Items
- Verify that the exchange closed and confirm the final principal amounts issued and remaining outstanding.
- Review the definitive indenture and New Note terms, including covenants, events of default, redemption provisions, and conversion adjustments.
- Assess the higher 8.00% cash interest burden and the impact of the $33.574 million New Notes on liquidity and future interest expense.
- Evaluate potential dilution using the initial conversion price and maximum stated conversion rate.
- Review subsequent filings for the final capitalization, accounting treatment, and any changes to debt maturity or liquidity risk.